A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
This study is testing an experimental medication called VVD-159642, both by itself and combined with other cancer drugs, in adults with advanced solid tumors. Researchers want to find the safest and most effective dose to help fight tumors that have spread.
You may be able to join if you have advanced cancer that has spread or cannot be removed by surgery, and you are generally active and well. Your lab tests for blood, liver, and kidney function must also be within safe ranges.
You will receive the study medication either alone or alongside other approved cancer therapies while doctors closely monitor your health. Regular check-ups, scans, and blood tests will be done to see how your body and your tumor respond to the treatment.
This study is currently recruiting participants at medical centers in Grand Rapids, Michigan, and cities across Texas like Austin and Irving.
- 1Testing a new cancer drug called VVD-159642 for advanced solid tumors
- 2Study involves taking the new medication alone or combined with other therapies
- 3Currently recruiting patients at multiple locations in Michigan and Texas
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.